Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-   B1188 Lenalidomide hemihydrateSummary: TNF-α secretion inhibitor B1188 Lenalidomide hemihydrateSummary: TNF-α secretion inhibitor
-   N2172 5,7-dihydroxychromone1 CitationTarget: Nrf2/ARE signal|PPARSummary: Nrf2/ARE signal activator and PPARγ agonist N2172 5,7-dihydroxychromone1 CitationTarget: Nrf2/ARE signal|PPARSummary: Nrf2/ARE signal activator and PPARγ agonist
-   A4204 JNJ-26854165 (Serdemetan)1 CitationTarget: p53|HDM2 ubiquitin ligaseSummary: P53 activator, blocking Mdm2-p53 interaction A4204 JNJ-26854165 (Serdemetan)1 CitationTarget: p53|HDM2 ubiquitin ligaseSummary: P53 activator, blocking Mdm2-p53 interaction
-   A4200 Apogossypolone (ApoG2)2 CitationTarget: Bcl-2|Bcl-xl|Mcl-1Summary: Bcl-2 inhibitor,nonpeptidic small molecule A4200 Apogossypolone (ApoG2)2 CitationTarget: Bcl-2|Bcl-xl|Mcl-1Summary: Bcl-2 inhibitor,nonpeptidic small molecule
-   A1923 Z-VEID-FMK2 CitationTarget: CaspasesSummary: Caspase-6 inhibitor A1923 Z-VEID-FMK2 CitationTarget: CaspasesSummary: Caspase-6 inhibitor
-   A8235 EmbelinSummary: XIAP inhibitor,cell-permeable A8235 EmbelinSummary: XIAP inhibitor,cell-permeable
-   A8236 Regorafenib4 CitationTarget: Raf|VEGFR|PDGFR|c-Kit|RETSummary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1 A8236 Regorafenib4 CitationTarget: Raf|VEGFR|PDGFR|c-Kit|RETSummary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
-   B7790 UC 112Summary: IAP inhibitor B7790 UC 112Summary: IAP inhibitor
-   B6163 A-11554632 CitationSummary: BCL-XL inhibitor, potent and selective B6163 A-11554632 CitationSummary: BCL-XL inhibitor, potent and selective
-   C5715 NK 252Summary: Nrf2 activator C5715 NK 252Summary: Nrf2 activator

